VioQuest Pharmaceuticals, Inc.

Form 4 June 17, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

VioQuest Pharmaceuticals, Inc.

3. Date of Earliest Transaction

(Print or Type Responses)

(Last)

1. Name and Address of Reporting Person *

BECKER MICHAEL D

(First)

(Middle)

180 MT. AIRY ROAD, SUITE 102

(Street)

(Month/Day/Year) 06/13/2008

Symbol

[VQPH]

4. If Amendment, Date Original Filed(Month/Day/Year)

BASKING RIDGE, NJ 07920

5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading

Issuer

(Check all applicable)

_X__ Director 10% Owner X_ Officer (give title Other (specify

below) below) President and CEO

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

Code (Instr. 8)

3.

Disposed of (D)

4. Securities

TransactionAcquired (A) or (Instr. 3, 4 and 5) Securities Beneficially Owned Following Reported

5. Amount of

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) (Instr. 4)

Ownership (Instr. 4)

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Transaction(s) (Instr. 3 and 4)

or Code V Amount (D) Price

(A)

Common Stock

 $5,000^{(1)}$ D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number or Derivative Acquired (Approximately Disposed of (Instr. 3, 4,	Securities A) or f (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Secur (Instr. 3 and 4)	
	·			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Am Nur Sha
Stock Options	\$ 3 (1)	06/13/2008		D <u>(2)</u>	()	501,334	(2)	11/21/2017	Common Stock, \$.001 par value	50
Stock Options	\$ 0.54	06/13/2008		A(2)	501,334		(2)	11/21/2017	Common Stock, \$.001 par value	50
Stock Options	\$ 3 (1)	06/13/2008		D <u>(3)</u>		29,974 (1)	(3)	11/21/2017	Common Stock, \$.001 par value	29
Stock Options	\$ 0.54	06/13/2008		A(3)	29,974		(3)	11/21/2017	Common Stock, \$.001 par value	29
Stock Options	\$ 0.54	06/13/2008		A	20,000		<u>(5)</u>	06/13/2018	Common Stock, \$.001 par value	20

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BECKER MICHAEL D							
180 MT. AIRY ROAD, SUITE 102	X		President and CEO				
BASKING RIDGE, NJ 07920							

Signatures

/s/ Michael D.

Becker 06/16/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

- (1) Adjusted to reflect a 1-for-10 reverse stock split effective on 4/25/08.
- This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 11/21/2007 and provided for vesting in four equal annual installments beginning on 11/21/2008.
 - This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of
- (3) a replacement option. The option was originally granted on 11/21/2007 and provided for vesting under certain contingencies. 21,410 shares vest on 11/21/08 and 8,564 vest on 11/21/09.
- (4) Pursuant to Rule 16b-3 (right to buy); issued under the 2003 Stock Option Plan.
- (5) 6,667 shares vest immediately; 6,667 shares vest on 6/13/09 and 6,666 shares vest on 6/13/10.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.